Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) Other Operating Expenses: 2016-2024

Historic Other Operating Expenses for Autolus Therapeutics (AUTL) over the last 9 years, with Dec 2024 value amounting to -$223,000.

  • Autolus Therapeutics' Other Operating Expenses rose 12944.39% to $28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.5 million, marking a year-over-year decrease of 63.45%. This contributed to the annual value of -$223,000 for FY2024, which is 94.12% up from last year.
  • As of FY2024, Autolus Therapeutics' Other Operating Expenses stood at -$223,000, which was up 94.12% from -$3.8 million recorded in FY2023.
  • Autolus Therapeutics' Other Operating Expenses' 5-year high stood at $2.8 million during FY2020, with a 5-year trough of -$3.8 million in FY2023.
  • In the last 3 years, Autolus Therapeutics' Other Operating Expenses had a median value of -$515,000 in 2022 and averaged -$1.5 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first surged by 100.84% in 2020, then plummeted by 636.12% in 2023.
  • Over the past 5 years, Autolus Therapeutics' Other Operating Expenses (Yearly) stood at $2.8 million in 2020, then plummeted by 124.19% to -$676,000 in 2021, then climbed by 23.82% to -$515,000 in 2022, then plummeted by 636.12% to -$3.8 million in 2023, then surged by 94.12% to -$223,000 in 2024.